Book

Cancer remains one of the most complex and challenging diseases of our time, creating an urgent need for innovative, precise, and effective therapeutic strategies. Enzyme inhibition has emerged as a powerful approach in modern oncology because many enzymes regulate critical processes involved in tumor growth, survival, invasion, metabolism, and treatment resistance. The edited book, “Enzyme Inhibition in Cancer Therapy: Unlocking New Frontiers in Drug Discovery,” presents a comprehensive and accessible overview of this rapidly evolving field, linking fundamental concepts with contemporary therapeutic applications. The book is organized into two major sections. The first establishes the scientific foundations of enzyme inhibition and drug discovery. It examines mechanisms and types of enzyme inhibition, enzyme structure and function, structural biology, molecular interactions, computational and in silico approaches, lead identification and optimization, and pharmacokinetic considerations. These chapters provide readers with a strong framework for understanding how enzyme inhibitors are designed, evaluated, and developed as potential anticancer agents. The second section focuses on clinical and therapeutic applications, highlighting enzymes that contribute to cancer initiation and progression. It explores important enzyme targets and inhibitor classes, including kinases, proteases, polymerases, and other emerging molecular targets. The chapters discuss their biological significance, mechanisms of action, therapeutic potential, and challenges associated with clinical translation. Particular attention is given to drug resistance, target selectivity, combination strategies, emerging technologies, and new enzyme targets that may shape the future of cancer therapy. Bringing together perspectives from pharmaceutical sciences, medicinal chemistry, molecular biology, computational drug discovery, pharmacology, and clinical research, this book offers an integrated view of enzyme-targeted cancer therapies. Written in clear and accessible language, it is designed for undergraduate and postgraduate students, researchers, academicians, healthcare professionals.